Non-neutralizing antibodies in prevention of HIV infection

Bibliography

• Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992;267(11):1489-94
   PubMed Web of Science ®Google Scholar
• Anttila M, Eskola J, Ahman H, Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998;177(6):1614-21
   PubMed Web of Science ®Google Scholar
• Yang X, Kurteva S, Ren X, Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 2005;79(19):12132-47
   PubMed Web of Science ®Google Scholar
• Daeron M. Fc receptor biology. Annu Rev Immunol 1997;15:203-34
   PubMed Web of Science ®Google Scholar
• Holl V, Peressin M, Schmidt S, Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006;107(11):4466-74
   PubMed Web of Science ®Google Scholar
• Holl V, Peressin M, Decoville T, Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006;80(12):6177-81
   PubMed Web of Science ®Google Scholar
• Moldt B, Schultz N, Dunlop DC, A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for fc{gamma}rs to define the role of effector functions in protection against HIV. J Virol 2011;85(20):10572-81
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Bream J, FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007;179(11):7916-23
   PubMed Web of Science ®Google Scholar
• Mabuka J, Nduati R, Odem-Davis K, HIV-specific Antibodies Capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012;8(6):e1002739
   PubMed Web of Science ®Google Scholar
• Baum LL, Cassutt KJ, Knigge K, HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157(5):2168-73
   PubMed Web of Science ®Google Scholar
• Lambotte O, Ferrari G, Moog C, Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009;23(8):897-906
   PubMed Web of Science ®Google Scholar
• Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007;262(1):5-25
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005;79(4):2042-9
   PubMed Web of Science ®Google Scholar
• Sullivan BL, Knopoff EJ, Saifuddin M, Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996;157(4):1791-8
   PubMed Web of Science ®Google Scholar
• Huber M, von Wyl V, Ammann CG, Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008;82(8):3834-42
   PubMed Web of Science ®Google Scholar
• Lai SK, Hida K, Shukair S, Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009;83(21):11196-200
   PubMed Web of Science ®Google Scholar
• Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998;280(5371):1884-8
   PubMed Web of Science ®Google Scholar
• Kwong PD, Doyle ML, Casper DJ, HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420(6916):678-82
   PubMed Web of Science ®Google Scholar
• Shen X, Parks RJ, Montefiori DC, In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009;83(8):3617-25
   PubMed Web of Science ®Google Scholar
• Mikell I, Sather DN, Kalams SA, Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011;7(1):e1001251
   PubMed Web of Science ®Google Scholar
• Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337(6091):183-6
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30(5):423-33
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654-65
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194(12):1661-71
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-93
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-20
   PubMed Web of Science ®Google Scholar
• Robb ML, Rerks-Ngarm S, Nitayaphan S, Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12(7):531-7
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-86
   PubMed Web of Science ®Google Scholar
• Bonsignori M. ADCC-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; In press
   Web of Science ®Google Scholar
• Pinter A, Honnen WJ, Kayman SC, Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998;16(19):1803-11
   PubMed Web of Science ®Google Scholar
• Rolland M, Edlefsen PT, Larsen BB, Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012;490:417-20
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-9
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Hwang KK, Chen X, Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011;85(19):9998-10009
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Karnasuta C, Huang Y, Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012;206(3):431-41
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Montefiori DC, Wu X, Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012;86(8):4688-92
   PubMed Web of Science ®Google Scholar
• Ferrari G, Pollara J, Kozink D, An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85(14):7029-36
   PubMed Web of Science ®Google Scholar
• Mathew GD, Qualtiere LF, Neel HB III, Pearson GR. IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 1981;27(2):175-80
   PubMed Web of Science ®Google Scholar
• Griffiss JM, Goroff DK. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol 1983;130(6):2882-5
   PubMed Web of Science ®Google Scholar
• Quan CP, Watanabe S, Forestier F, Bouvet JP. Human amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin. Eur J Immunol 1998;28(12):4001-9
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa S, Kozlowski PA, Prevention of infection by a granulocyte-macrophage colony-stimualting factor co-expressing DNA/modified •vaccinia ankara simian immunodeficiency virus vaccine. J Infect Dis 2011;204:164-73
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482(7383):89-93
   PubMed Web of Science ®Google Scholar
• Lai L, Vodros D, Kozlowski PA, GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007;369(1):153-67
   PubMed Web of Science ®Google Scholar
• Zhao J, Lai L, Amara RR, Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009;83(9):4102-11
   PubMed Web of Science ®Google Scholar
• Hidajat R, Xiao P, Zhou Q, Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009;83(2):791-801
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ, Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010;84(14):7161-73
   PubMed Web of Science ®Google Scholar
• Barnett SW, Burke B, Sun Y, Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010;84(12):5975-85
   PubMed Web of Science ®Google Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG, A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012;86(11):6189-96
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449(7158):101-4
   PubMed Web of Science ®Google Scholar
• Burton DR, Hessell AJ, Keele BF, Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011;108(27):11181-6
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Berardi CJ, Dillard-Telm S, Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998;177(5):1247-59
   PubMed Web of Science ®Google Scholar
• Florese RH, Van Rompay KK, Aldrich K, Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006;177(6):4028-36
   PubMed Web of Science ®Google Scholar
• Chung AW, Isitman G, Navis M, Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011;108(18):7505-10
   PubMed Web of Science ®Google Scholar
• Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178(10):6596-603
   PubMed Web of Science ®Google Scholar
• Wu X, Zhou T, Zhu J, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333(6049):1593-602
   PubMed Web of Science ®Google Scholar
• Sundling C, Forsell MN, O'Dell S, Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010;207(9):2003-17
   PubMed Web of Science ®Google Scholar
• Li GM, Chiu C, Wrammert J, Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012;109(23):9047-52
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Hannan CM, Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999;170:29-38
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa SF, Kozlowski PA, SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012;30(9):1737-45
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654-65
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scheid JF, Zoller MJ, Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467(7315):591-5
   PubMed Web of Science ®Google Scholar
• Jeffs SA, Goriup S, Kebble B, Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004;22(8):1032-46
   PubMed Web of Science ®Google Scholar
• Yang X, Lee J, Mahony EM, Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76(9):4634-42
   PubMed Web of Science ®Google Scholar
• Amara RR. CD40L expressed on virus-like particles adjuvants prevention of acquistion mediated by a DNA/MVA vaccine. AIDS Vaccine; Atlanta, GA: 2010
   Google Scholar
• Khurana S, Verma N, Yewdell JW, MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011;3(85):85ra48
   PubMed Web of Science ®Google Scholar
• Parekh BS, Pau CP, Kennedy MS, Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res Hum Retroviruses 2001;17(2):137-46
   PubMed Web of Science ®Google Scholar
• Duong YT, Qiu M, De AK, Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for hiv-1 incidence estimates and avidity maturation studies. PLoS One 2012;7(3):e33328
   PubMed Web of Science ®Google Scholar
• Wei X, Liu X, Dobbs T, Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010;26(1):61-71
   PubMed Web of Science ®Google Scholar
• Fernandez-Larsson R, Srivastava KK, Lu S, Robinson HL. Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. Proc Natl Acad Sci USA 1992;89(6):2223-6
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Nigam P, Velu V, Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA Vaccine. J Immunol 2010;185(12):7262-73
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Moldt B, Wyatt RT, A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011;366(1-2):8-19
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001;75(15):6953-61
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Elizaga ML, Sato A, Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011;203(5):610-19
   PubMed Web of Science ®Google Scholar
• Parekh BS, Kennedy MS, Dobbs T, Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002;18(4):295-307
   PubMed Web of Science ®Google Scholar